About the Company
VeriStrat is a test developed to evaluate patient prognosis and, additionally, predict benefit from cancer treatment by EGFR inhibitors. It is a serum/plasma proteomic test developed using matrix-assisted laser desorption/ionization (MALDI) mass spectrometry. VeriStrat was developed by Biodesix, Inc., a molecular diagnostics company based in Boulder, Colorado, US. The VeriStrat algorithm has been interrogated retrospectively and prospectively in samples from randomized trials, such as the PROSE study, confirming the prognostic information associated with the molecular signature. In addition, the test appeared to be predictive of erlotinib impact on survival, as only "VeriStrat Good patients" benefited from such a treatment. Additional studies have confirmed its clinical relevance.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $BDSX News
Biodesix, Inc. (BDSX)
LOUISVILLE, Colo., August 07, 2024--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced its financial and operating results for the second quarter ended June 30 ...
Biodesix to Present at Two Investor Conferences in September
Biodesix is a leading diagnostic solutions company with five Medicare-covered tests available for patients with lung diseases. The blood-based Nodify Lung® Nodule Risk Assessment, consisting of ...
Biodesix to Present at Canaccord Genuity’s 44th Annual Growth Conference
LOUISVILLE, Colo.--(BUSINESS WIRE)-- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, announced today that Scott Hutton, Chief Executive Officer ...
Q3 2024 EPS Estimates for Biodesix, Inc. (NASDAQ:BDSX) Decreased by William Blair
Biodesix, Inc. (NASDAQ:BDSX – Free Report) – Equities researchers at William Blair decreased their Q3 2024 earnings per share estimates for shares of Biodesix in a research note issued to ...
Biodesix executive sells over $300 in stock, prices range $1.52 to $1.64
Biodesix Inc (NASDAQ:BDSX) reported that its Chief Accounting Officer, Chris Vazquez, sold a total of $333 worth of common stock, according to a recent SEC filing. The transactions occurred in a ...
Biodesix Announces Second Quarter 2024 Results and Highlights
Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced its financial and operating results for the second quarter ended June 30, 2024. “The second quarter marks ...
Buy Rating Justified: Biodesix’s Strong Q2 Performance and Growth Prospects
Begin your TipRanks Premium journey today. Biodesix (BDSX) Company Description: Biodesix Inc is a data-driven diagnostic solutions company. The company’s artificial intelligence-based platform ...
Biodesix Inc Ordinary Shares
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Biodesix CFO sells over $1,500 in company stock
Biodesix Inc (NASDAQ:BDSX) CFO, Secretary, and Treasurer Robin Harper Cowie has sold a total of $1,553 worth of company stock, according to recent SEC filings. The transactions involved the sale of ...
Biodesix to Present at Two Investor Conferences in September
Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, announced today that ...
Biodesix executive sells over $300 in stock, prices range $1.52 to $1.64
Biodesix Inc (NASDAQ:BDSX) reported that its Chief Accounting Officer, Chris Vazquez, sold a total of $333 worth of common stock, according to a recent SEC filing. The transactions occurred in a ...
Loading the latest forecasts...